Diabetes Clinic

Paphos, Cyprus

Diabetes Clinic

Paphos, Cyprus

Time filter

Source Type

News Article | June 5, 2017
Site: globenewswire.com

BRIDGEWATER, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will host an Investor Reception and webcast on Saturday, June 10 during the American Diabetes Association (ADA) 77th Scientific Sessions in San Diego. The reception will feature two key opinion leaders, Mark Peyrot, PhD, discussing medication therapy and challenges in facilitating implementation of Insulin therapy with patients who have diabetes and Martin Sarkar, DO, discussing how the V-Go ® Wearable Insulin Delivery device can address many of these challenges. Attendance at the event is open to institutional investors and equity analysts. If interested in attending the Investor Day, please reach out to Brian Johnston at bjohnston@theruthgroup.com to register. Note that registration is required to attend the event.  A live webcast of the event will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com and remain available for 90 days. Mark Peyrot, PhD, is a Professor of Sociology at Loyola University Maryland and Professor of Health and Social Sciences at Bergen University College (Norway).  Formerly, he was a faculty member in the departments of Sociology and Medicine at the University of Kentucky and Medicine at Johns Hopkins University. His recent projects comprise multiple funded studies, including: surveys of psychosocial and behavioral outcomes and determinants among diabetes patients, their family members and health care providers (e.g., the DAWN and DAWN2 studies); studies of patient reported outcomes in diabetes clinical trials (e.g., adherence, treatment satisfaction and quality of life); and studies of the drivers, consequences and relationships among diabetes, depression, and complications of diabetes. He has served leadership roles within ADA and AADE and was one of the developers of the AADE National Diabetes Education Outcome System, the AADE7 Self-care Behaviors, the ADA/AADE National Standards for Diabetes Self-management Education and the AADE National Standards for Outcomes Measurement of Diabetes Self-management Education. His 300+ publications include a co-edited collection of diabetes psychosocial care guidelines and a ADA position statement on diabetes psychosocial care recently published by ADA. Martin Sarkar, DO, is a Staff Endocrinologist with Monocacy Health Partners Endocrine and Thyroid Specialists at Frederick Regional Health System in Frederick, MD. He received his medical degree from West Virginia School of Osteopathic Medicine, completed his internship and residency training in internal medicine at Eisenhower Army Medical Center, and completed his fellowship in endocrinology and metabolism at the Medical College of Georgia. He was previously Chief of Medicine and Medical Director of the Diabetes Clinic at Munson Army Medical Center - Fort Leavenworth, KS.  Dr. Sarkar has been awarded many Army Commendation and Achievement medals as well as the Meritorious Service Medal for his service as Battalion Surgeon of the 3rd Infantry Division of the U.S. Army during Operation Iraqi Freedom. His clinical focus is in the management of diabetes, its complications and associated comorbidities. He has received multiple awards for excellence in patient care. He has been an investigator and sub-investigator for various research protocols for the Army Medical Corps and the Georgia Prevention Institute. He has numerous presentations regionally and nationally. Dr. Sarkar is on the speaker’s bureau for AstraZeneca, Medtronic, and Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.


News Article | June 5, 2017
Site: globenewswire.com

BRIDGEWATER, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will host an Investor Reception and webcast on Saturday, June 10 during the American Diabetes Association (ADA) 77th Scientific Sessions in San Diego. The reception will feature two key opinion leaders, Mark Peyrot, PhD, discussing medication therapy and challenges in facilitating implementation of Insulin therapy with patients who have diabetes and Martin Sarkar, DO, discussing how the V-Go ® Wearable Insulin Delivery device can address many of these challenges. Attendance at the event is open to institutional investors and equity analysts. If interested in attending the Investor Day, please reach out to Brian Johnston at bjohnston@theruthgroup.com to register. Note that registration is required to attend the event.  A live webcast of the event will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com and remain available for 90 days. Mark Peyrot, PhD, is a Professor of Sociology at Loyola University Maryland and Professor of Health and Social Sciences at Bergen University College (Norway).  Formerly, he was a faculty member in the departments of Sociology and Medicine at the University of Kentucky and Medicine at Johns Hopkins University. His recent projects comprise multiple funded studies, including: surveys of psychosocial and behavioral outcomes and determinants among diabetes patients, their family members and health care providers (e.g., the DAWN and DAWN2 studies); studies of patient reported outcomes in diabetes clinical trials (e.g., adherence, treatment satisfaction and quality of life); and studies of the drivers, consequences and relationships among diabetes, depression, and complications of diabetes. He has served leadership roles within ADA and AADE and was one of the developers of the AADE National Diabetes Education Outcome System, the AADE7 Self-care Behaviors, the ADA/AADE National Standards for Diabetes Self-management Education and the AADE National Standards for Outcomes Measurement of Diabetes Self-management Education. His 300+ publications include a co-edited collection of diabetes psychosocial care guidelines and a ADA position statement on diabetes psychosocial care recently published by ADA. Martin Sarkar, DO, is a Staff Endocrinologist with Monocacy Health Partners Endocrine and Thyroid Specialists at Frederick Regional Health System in Frederick, MD. He received his medical degree from West Virginia School of Osteopathic Medicine, completed his internship and residency training in internal medicine at Eisenhower Army Medical Center, and completed his fellowship in endocrinology and metabolism at the Medical College of Georgia. He was previously Chief of Medicine and Medical Director of the Diabetes Clinic at Munson Army Medical Center - Fort Leavenworth, KS.  Dr. Sarkar has been awarded many Army Commendation and Achievement medals as well as the Meritorious Service Medal for his service as Battalion Surgeon of the 3rd Infantry Division of the U.S. Army during Operation Iraqi Freedom. His clinical focus is in the management of diabetes, its complications and associated comorbidities. He has received multiple awards for excellence in patient care. He has been an investigator and sub-investigator for various research protocols for the Army Medical Corps and the Georgia Prevention Institute. He has numerous presentations regionally and nationally. Dr. Sarkar is on the speaker’s bureau for AstraZeneca, Medtronic, and Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.


News Article | June 5, 2017
Site: globenewswire.com

BRIDGEWATER, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will host an Investor Reception and webcast on Saturday, June 10 during the American Diabetes Association (ADA) 77th Scientific Sessions in San Diego. The reception will feature two key opinion leaders, Mark Peyrot, PhD, discussing medication therapy and challenges in facilitating implementation of Insulin therapy with patients who have diabetes and Martin Sarkar, DO, discussing how the V-Go ® Wearable Insulin Delivery device can address many of these challenges. Attendance at the event is open to institutional investors and equity analysts. If interested in attending the Investor Day, please reach out to Brian Johnston at bjohnston@theruthgroup.com to register. Note that registration is required to attend the event.  A live webcast of the event will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com and remain available for 90 days. Mark Peyrot, PhD, is a Professor of Sociology at Loyola University Maryland and Professor of Health and Social Sciences at Bergen University College (Norway).  Formerly, he was a faculty member in the departments of Sociology and Medicine at the University of Kentucky and Medicine at Johns Hopkins University. His recent projects comprise multiple funded studies, including: surveys of psychosocial and behavioral outcomes and determinants among diabetes patients, their family members and health care providers (e.g., the DAWN and DAWN2 studies); studies of patient reported outcomes in diabetes clinical trials (e.g., adherence, treatment satisfaction and quality of life); and studies of the drivers, consequences and relationships among diabetes, depression, and complications of diabetes. He has served leadership roles within ADA and AADE and was one of the developers of the AADE National Diabetes Education Outcome System, the AADE7 Self-care Behaviors, the ADA/AADE National Standards for Diabetes Self-management Education and the AADE National Standards for Outcomes Measurement of Diabetes Self-management Education. His 300+ publications include a co-edited collection of diabetes psychosocial care guidelines and a ADA position statement on diabetes psychosocial care recently published by ADA. Martin Sarkar, DO, is a Staff Endocrinologist with Monocacy Health Partners Endocrine and Thyroid Specialists at Frederick Regional Health System in Frederick, MD. He received his medical degree from West Virginia School of Osteopathic Medicine, completed his internship and residency training in internal medicine at Eisenhower Army Medical Center, and completed his fellowship in endocrinology and metabolism at the Medical College of Georgia. He was previously Chief of Medicine and Medical Director of the Diabetes Clinic at Munson Army Medical Center - Fort Leavenworth, KS.  Dr. Sarkar has been awarded many Army Commendation and Achievement medals as well as the Meritorious Service Medal for his service as Battalion Surgeon of the 3rd Infantry Division of the U.S. Army during Operation Iraqi Freedom. His clinical focus is in the management of diabetes, its complications and associated comorbidities. He has received multiple awards for excellence in patient care. He has been an investigator and sub-investigator for various research protocols for the Army Medical Corps and the Georgia Prevention Institute. He has numerous presentations regionally and nationally. Dr. Sarkar is on the speaker’s bureau for AstraZeneca, Medtronic, and Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.


News Article | June 5, 2017
Site: globenewswire.com

BRIDGEWATER, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will host an Investor Reception and webcast on Saturday, June 10 during the American Diabetes Association (ADA) 77th Scientific Sessions in San Diego. The reception will feature two key opinion leaders, Mark Peyrot, PhD, discussing medication therapy and challenges in facilitating implementation of Insulin therapy with patients who have diabetes and Martin Sarkar, DO, discussing how the V-Go ® Wearable Insulin Delivery device can address many of these challenges. Attendance at the event is open to institutional investors and equity analysts. If interested in attending the Investor Day, please reach out to Brian Johnston at bjohnston@theruthgroup.com to register. Note that registration is required to attend the event.  A live webcast of the event will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com and remain available for 90 days. Mark Peyrot, PhD, is a Professor of Sociology at Loyola University Maryland and Professor of Health and Social Sciences at Bergen University College (Norway).  Formerly, he was a faculty member in the departments of Sociology and Medicine at the University of Kentucky and Medicine at Johns Hopkins University. His recent projects comprise multiple funded studies, including: surveys of psychosocial and behavioral outcomes and determinants among diabetes patients, their family members and health care providers (e.g., the DAWN and DAWN2 studies); studies of patient reported outcomes in diabetes clinical trials (e.g., adherence, treatment satisfaction and quality of life); and studies of the drivers, consequences and relationships among diabetes, depression, and complications of diabetes. He has served leadership roles within ADA and AADE and was one of the developers of the AADE National Diabetes Education Outcome System, the AADE7 Self-care Behaviors, the ADA/AADE National Standards for Diabetes Self-management Education and the AADE National Standards for Outcomes Measurement of Diabetes Self-management Education. His 300+ publications include a co-edited collection of diabetes psychosocial care guidelines and a ADA position statement on diabetes psychosocial care recently published by ADA. Martin Sarkar, DO, is a Staff Endocrinologist with Monocacy Health Partners Endocrine and Thyroid Specialists at Frederick Regional Health System in Frederick, MD. He received his medical degree from West Virginia School of Osteopathic Medicine, completed his internship and residency training in internal medicine at Eisenhower Army Medical Center, and completed his fellowship in endocrinology and metabolism at the Medical College of Georgia. He was previously Chief of Medicine and Medical Director of the Diabetes Clinic at Munson Army Medical Center - Fort Leavenworth, KS.  Dr. Sarkar has been awarded many Army Commendation and Achievement medals as well as the Meritorious Service Medal for his service as Battalion Surgeon of the 3rd Infantry Division of the U.S. Army during Operation Iraqi Freedom. His clinical focus is in the management of diabetes, its complications and associated comorbidities. He has received multiple awards for excellence in patient care. He has been an investigator and sub-investigator for various research protocols for the Army Medical Corps and the Georgia Prevention Institute. He has numerous presentations regionally and nationally. Dr. Sarkar is on the speaker’s bureau for AstraZeneca, Medtronic, and Valeritas. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.


Papaetis G.S.,Diabetes Clinic | Papaetis G.S.,National and Kapodistrian University of Athens | Orphanidou D.,National and Kapodistrian University of Athens | Panagiotou T.N.,National and Kapodistrian University of Athens
Current Drug Targets | Year: 2011

The prevalence of type 2 diabetes is evolving globally at an alarming rate. This fact is mainly the result of our global lifestyle "modernization" that has resulted in overweight and obesity. Dysfunction of peroxisome proliferators activated receptor-gamma (PPAR-γ) has been implicated in the development of insulin resistance, while a reduce expression of many PPAR-γ regulated genes has been observed in an obese diabetic state. Thiazolidinediones (TZDs) are potent exogenous agonists of PPAR-γ, which augment the effects of insulin to its cellular targets and mainly at the level of adipose tissue. Preclinical and clinical studies have demonstrated that apart from their glucose-lowering activity, these drugs also regulate the production of inflammatory mediators by cells that play a pivotal role in the pathogenesis of atherosclerosis. This paper summarizes the evolving changes observed in an enlarged adipose tissue and examines the activity of TZDs in their main cellular targets. It also discusses whether these cellular pleiotropic effects can result in a clinically meaningful outcome, in terms of cardiovascular benefit, in this population. © 2011 Bentham Science Publishers Ltd.


Papaetis G.S.,Diabetes Clinic | Papaetis G.S.,National and Kapodistrian University of Athens | Papakyriakou P.,Paphos General Hospital | Panagiotou T.N.,National and Kapodistrian University of Athens
Archives of Medical Science | Year: 2015

The prevalence of type 2 diabetes (T2D) is rapidly increasing. This is strongly related to the contemporary lifestyle changes that have resulted in increased rates of overweight individuals and obesity. Central (intra-abdominal) obesity is observed in the majority of patients with T2D. It is associated with insulin resistance, mainly at the level of skeletal muscle, adipose tissue and liver. The discovery of macrophage infiltration in the abdominal adipose tissue and the unbalanced production of adipocyte cytokines (adipokines) was an essential step towards novel research perspectives for a better understanding of the molecular mechanisms governing the development of insulin resistance. Furthermore, in an obese state, the increased cellular uptake of non-esterified fatty acids is exacerbated without any subsequent β-oxidation. This in turn contributes to the accumulation of intermediate lipid metabolites that cause defects in the insulin signaling pathway. This paper examines the possible cellular mechanisms that connect central obesity with defects in the insulin pathway. It discusses the discrepancies observed from studies organized in cell cultures, animal models and humans. Finally, it emphasizes the need for therapeutic strategies in order to achieve weight reduction in overweight and obese patients with T2D. Copyright © 2015 Termedia & Banach.


Kianbakht S.,Tehran University of Medical Sciences | Kianbakht S.,Research Institute of Medicinal Plants | Abasi B.,Diabetes Clinic | Dabaghian F.H.,Tehran University of Medical Sciences
Forschende Komplementarmedizin | Year: 2013

Background: Type 2 diabetes mellitus is a common disease. Preliminary data indicate that Vaccinium arctostaphylos L. (Caucasian whortleberry) has a potential effect in glycemic control. Thus, the efficacy and safety of a standardized whortleberry fruit hydroalcoholic extract in the treatment of type 2 diabetic patients were studied. Methods: This randomized double-blind placebo-controlled clinical trial consisted of 37 patients aged 40-60 years with type 2 diabetes who were resistant to conventional oral anti-hyperglycemic drugs. The patients were treated with the whortleberry fruit hydroalcoholic extract (1 capsule = 350 mg, every 8 h for 2 months) in combination with anti-hyperglycemic drugs, and the effects on the blood levels of fasting glucose, 2-hour postprandial glucose, glycosylated hemoglobin (HbA1c), and liver/kidney function were tested, evaluated, and compared with a placebo group (n = 37). Results: The extract significantly lowered the blood levels of fasting glucose, 2-h postprandial glucose, and HbA1c (p = 0.007, p <0.001, and p = 0.005, respectively) without any significant effects on the liver/kidney function (p >0.05) compared with placebo at the end. No adverse effects were reported. Conclusion: Whortleberry may safely improve glycemic control in type 2 diabetic patients. © 2013 S. Karger AG, Basel.


Kianbakht S.,Tehran University of Medical Sciences | Kianbakht S.,Research Institute of Medicinal Plants | Abasi B.,Diabetes Clinic | Dabaghian F.H.,Tehran University of Medical Sciences
Forschende Komplementarmedizin | Year: 2013

Background: Type 2 diabetes mellitus is a common disease. Preliminary data indicate that Vaccinium arctostaphylos L. (Caucasian whortleberry) has a potential effect in glycemic control. Thus, the efficacy and safety of a standardized whortleberry fruit hydroalcoholic extract in the treatment of type 2 diabetic patients were studied. Methods: This randomized double-blind placebo-controlled clinical trial consisted of 37 patients aged 40-60 years with type 2 diabetes who were resistant to conventional oral anti-hyperglycemic drugs. The patients were treated with the whortleberry fruit hydroalcoholic extract (1 capsule = 350 mg, every 8 h for 2 months) in combination with anti-hyperglycemic drugs, and the effects on the blood levels of fasting glucose, 2-hour postprandial glucose, glycosylated hemoglobin (HbA1c), and liver/kidney function were tested, evaluated, and compared with a placebo group (n = 37). Results: The extract significantly lowered the blood levels of fasting glucose, 2-h postprandial glucose, and HbA1c (p = 0.007, p <0.001, and p = 0.005, respectively) without any significant effects on the liver/kidney function (p >0.05) compared with placebo at the end. No adverse effects were reported. Conclusion: Whortleberry may safely improve glycemic control in type 2 diabetic patients. Copyright © 2013 S. Karger AG, Basel.


We performed a non-inferiority trial comparing insulin detemir (Levemir) and biphasic insulin (NovoMix70) to standard care during Ramadan fast in insulin treated type 2 diabetes mellitus (T2DM) patients. This was an open label, controlled, multicentre, cluster randomised non-inferiority study. Insulin treated T2DM patients from 12 randomly selected primary clinics received Levemir and NovoMix 70 (intervention, n = 127) or standard care according to the American Diabetes Association recommendations (control, n = 118). Insulin dose (intervention) was 60% of the usual, of this 40% was dosed as Levemir at sunrise and 60% as NovoMix 70 before dinner. Insulin was titrated according to daily 4 point self-measured blood glucose (4P-SMBG) levels. The primary outcome was the difference in mean daily 4P-SMBG during days 23-30 of treatment. Mean age was 60.1 (SD 8.9) and 59.4 (SD 10.1) years in the intervention and control respectively. Mean HbA1c was 8.38% (68 mmol/mol) (SD 0.96) and 8.45% (69 mmol/mol) (SD 1.08). Mean BMI was 32.99 (SD 7.05) and 33.08 (SD 7.24), respectively. The intervention was non-inferior to standard care as assessed by mean 4P-SMBG during days 23-30 of treatment [155 (SD 30.76) mg% and 159 (SD 33.24) mg% respectively, p = 0.269]. Adverse event rate was significantly lower in the intervention group [0.04 (SD 0.06) vs. 0.07 (SD 0.11), p = 0.010]. In particular, hypoglycaemia event rate was lower in the intervention group [0.00 (SD 0.01) vs. 0.01 (SD 0.03), p 0.001]. To conclude, treatment with Levemir and NovoMix 70 was non-inferior to standard care in this heterogeneous group of patients and was associated with less adverse events.


PubMed | Diabetes Clinic and Institute of Medicinal Plants
Type: Journal Article | Journal: International journal of molecular and cellular medicine | Year: 2016

The efficacy and safety of

Loading Diabetes Clinic collaborators
Loading Diabetes Clinic collaborators